Amgen's Q2 Results Exceed Expectations with Strong Revenue Growth

Amgen reported Q2 CY2026 results that exceeded market expectations. Revenue reached $10.05 billion, a 9.5% year-on-year increase and a 6.9% beat on analyst estimates.

The company's non-GAAP profit was $6.29 per share, 12% above analysts' consensus estimates. Amgen lifted its revenue guidance for the full year to $38.8 billion at the midpoint from $37.8 billion, a 2.6% increase.

CEO Robert Bradway attributed the strong quarterly performance to the expansion of high-growth products and disciplined R&D investment. He highlighted that 22 products achieved double-digit sales growth, and 17 products annualized over $1 billion in sales.